Skip To Main Content
Eromona Whiskey on Muck Rack

Eromona Whiskey

London
As seen in: Nature, Cambridge University Press & Assessment, The Lancet
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Eromona

Contact Eromona, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Evaluation of 96 cases of apparent clozapine-induced severe neutropenia

|
By Phoebe Wallman, Risha Govind, Cecilia Casetta, Eromona Whiskey
| Cambridge University Press & Assessment
Clozapine is underused in most countries. Reference Bachmann, Aagaard, Bernardo, Brandt, Cartabia and Clavenna1,Reference Whiskey, Barnard, Oloyede, Dzahini, Taylor and Shergill2 There are many reasons for this underuse, but the burden of blood testing is a frequently cited cause.
Open in Who Shared Issue with article?

The paradox of clozapine in Black people with treatment-resistant schizophrenia - Nature Mental Health

|
By Eromona Whiskey, Olubanke Dzahini
| Nature Verified
Abstract Clozapine is currently the only licensed medication for treatment-resistant schizophrenia (TRS). Ethnic inequalities in treatment with clozapine have been described extensively, particularly regarding the effect on Black ethnic groups. Here we explore the reasons for clozapine underuse in this population, identifying potential misconceptions and providing suggestions to address these barriers.
Open in Who Shared Issue with article?

Relaxation of the criteria for entry to the UK Clozapine Central Non-Rechallenge Database: a modelling study

|
By Ebenezer Oloyede, South London, Eromona Whiskey
| The Lancet Verified
Clozapine is uniquely effective in treatment-resistant psychosis. In the UK, patients must discontinue clozapine indefinitely if they are placed on the Central Non-Rechallenge Database (CNRD) after their haematological parameters fall below particular thresholds. Under exceptional circumstances, patients can be rechallenged on clozapine under an off-licence agreement. In the USA in 2015, restrictive practice was discontinued to allow greater flexibility for clozapine maintenance.
Open in Who Shared Issue with article?
See all 8 articles